Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5Expanded_access 1

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × mobocertinib × Clear all
NCT03807778 2026-05-14

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

Takeda

Phase 1 Active not recruiting
53 enrolled 38 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04129502 2026-03-30

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Takeda

Phase 3 Active not recruiting
354 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02716116 2026-02-25

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Takeda

Phase 1/2 Active not recruiting
334 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04051827 2025-07-28

Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Takeda

Phase 1 Completed
26 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04576208 2020-12-17

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Takeda

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡